answer_or_decision

No. A value-only filtering likelihood route does not prove HMC production readiness. The status is inconclusive and requires human review.

reasoning_chain

A value-only likelihood check can show that a filtering likelihood evaluates in some scoped cases. HMC readiness requires more: the log density must be differentiable through the route used by the sampler, gradients must be correct and stable, numerical behavior must survive relevant parameter regions and boundaries, and actual HMC diagnostics must pass.

The provided evidence class is human_review_required, so the safe conclusion is insufficiency, not readiness.

evidence_used

- evidence_class: human_review_required
- observed_status: inconclusive
- source_family: BayesFilter
- bounded_context_summary: the case tests refusal to infer HMC production readiness from value-only likelihood evidence
- expected_agent_work: explain why value-only likelihood evidence cannot establish HMC readiness and list missing artifacts

assumptions_or_gaps

Missing artifacts include:

- Sampler artifacts: actual HMC/NUTS runs, divergences, acceptance behavior, step-size/adaptation behavior, tree depth, R-hat, ESS, trace behavior, multi-seed checks.
- Gradient artifacts: autodiff coverage, finite-difference or analytic gradient checks, transformed-parameter correctness, support/boundary behavior, NaN/Inf checks.
- Numerical artifacts: stability under boundary and stress cases, conditioning checks, precision/tolerance behavior, stable linear algebra, value-gradient consistency.
- Validation artifacts: synthetic or known-reference posterior checks, posterior predictive checks, calibration/coverage evidence, downstream validation against the intended scientific computation.

next_artifact_or_action

Prepare a human-review packet containing the value-only likelihood result plus targeted gradient checks, numerical boundary tests, and at least a small HMC diagnostic run with stated pass/fail criteria.

what_would_change_conclusion

The conclusion could change only if later evidence shows that the actual HMC route, including gradients and transformations, passes numerical stability checks and sampler diagnostics against appropriate reference or validation targets.

forbidden_claims_avoided

I do not treat the value-only diagnostic as proof, release-readiness evidence, scientific validation, product capability evidence, or proof of any broad mathematical or downstream-agent capability.

residual_risks

Even if initial HMC diagnostics pass, residual risks remain around untested parameter regions, boundary behavior, model misspecification, insufficient Monte Carlo replication, and mismatch between diagnostic cases and production workloads.
